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Alzheimer’s disease is a progressive irreversible neurodegenerative disorder that is 
globally associated with the most frequent cause of dementia. The pathophysiology of this 
illness is not fully understood yet. The commonly used treatment is still symptomatic, based on 
IAChE and memantine. Great attention is paid particularly to IAChEs and their derivatives, 
which arise from the basic structure of tacrine and 7-MEOTA. These two molecules were used 
as a reference for comparison with newly synthetized IAChE derivatives KB-36 and KB-38. 
Changes in plasma and brain tissue concentration levels were studied. The in vivo study 
was performed on rats (male, tribe Wistar). Equimolar doses were administered 
intramuscularly. Samples of plasma and brain tissue were evaluated by using HPLC techniques. 
The main aim was to determine the real concentration levels of all IAChE in both 
compartments. 
Our results showed that tacrine had a better blood-brain barrier permeation than 7-MEOTA. 
Maximal concentration of tacrine in brain tissue, 18.86 ng/ml, was achieved in the 30th minute. 
Maximal concentration of 7-MEOTA in brain tissue was 14.17 ng/ml and in was achieved in 
the 15th minute. New derivatives, KB-36 and KB-38, did not achieved brain tissue in therapeutic 
concentration order. Therefore it is unlikely that these new molecules could relieve Alzheimer’s 
disease symptoms. 
